Major pharmas show high interests in DGMIF’s ‘innovative renal cancer treatment technology’

Published: 2017-07-12 13:04:08

Updated: 2017-07-12 13:04:08

The Daegu-Gyeongbuk Medical Innovation Foundation(Chairman Jae-Tae Lee, DGMIF) have drawn huge interests of major Korean and multinational pharmaceutical companies with the ‘innovative renal cancer treatment’ at the ‘InterBiz Bio-Partnering & Investment Forum 2017’ in Jeju Island between the 5^th and 7^th of July.

The technology was co-developed by the Dr. Min-Soo Song’s team at the New Drub Dev...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.